Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.50 |
| ▸ | PPARA | Q07869 | 11/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888213 | 0.97 | PPARG (0.49) | PPARGPPARATSHRMAPK14PPARD | |
| SCHEMBL4891450 | 0.97 | PPARG (0.49) | PPARGPPARATSHRMAPK14PPARD | |
| SCHEMBL4896276 | 0.92 | PPARG (0.51) | PPARGPPARATSHRPPARD | |
| SCHEMBL4888233 | 0.90 | PPARG (0.49) | PPARGPPARATSHRPPARD | |
| SCHEMBL4885788 | 0.89 | PPARG (0.51) | PPARGPPARATSHR | |
| SCHEMBL4895315 | 0.87 | PPARG (0.48) | PPARGPPARATSHR | |
| SCHEMBL4895959 | 0.87 | PPARG (0.50) | PPARGPPARATSHRMAPK8 | |
| SCHEMBL4897935 | 0.87 | PPARG (0.48) | PPARGPPARATSHR | |
| SCHEMBL4893180 | 0.86 | PPARG (0.51) | PPARGPPARAMAPK14PPARDLTA4H | |
| SCHEMBL4889380 | 0.85 | PPARG (0.49) | PPARGPPARATSHRMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007122277-A1 | 4-ACYLOYLOXY-2H-1,4-BENZOXAZIN-3-(4H)ONE DERIVATIVES WITH PHYTOTOXIC ACTIVITY | UNIVERSIDAD DE CÁDIZ (ES) | 2007-11-01 | — | — | WO | claimed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | GOSSETT LYNN STACY | 2008-07-10 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282501-B2 | Modulators of peroxisome proliferator activated receptors (PPAR) | ELI LILLY AND COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| EP-1401434-B1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | LILLY CO ELI (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | ELI LILLY AND COMPANY | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075378-A1 | Modulators of peroxisome proliferator activated receptors (ppar) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885TSHR 1255/4885 |
| US-20080167310-A1 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS (PPAR) | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885TSHR 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.